Introduction
============

Postoperative sore throat (POST) is common after tracheal intubation of general anesthesia. Numerous factors including age, female gender, smoking history, size of the endotracheal tube, cuff pressure, time and manipulations needed to insert the tube, and time of operation and anesthesia may affect the incidence of POST, with discomfort and dissatisfaction.[@b1-jpr-11-2463]--[@b3-jpr-11-2463]

A previous systematic review and meta-analysis demonstrated that single low-dose corticosteroids can provide pain relief in patients with sore throat, with no increase in serious adverse effects.[@b4-jpr-11-2463] Considering the involvement of inflammation in pathophysiology of POST, the use of steroidal or nonsteroidal anti-inflammation drug may be an effective pharmacological strategy to prevent POST after tracheal intubation. As glucocorticoid, dexamethasone was supposed to have anti-inflammatory and analgesic impact.[@b5-jpr-11-2463],[@b6-jpr-11-2463] A previous systematic review and meta-analysis has demonstrated a significant reduction in the incidence of POST from intubation at 24 hours in patients treated with intravenous dexamethasone compared with placebo,[@b7-jpr-11-2463] with similar results as another one.[@b8-jpr-11-2463] However, the relatively small sample size included in both the reviews precluded the authors from drawing definitive conclusions, and the optimal timing of dexamethasone administration, and combination effect of dexamethasone with other medicines, remains unclear.

Therefore, we conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the impact of prophylactic dexamethasone on POST for tracheal intubation of general anesthesia.

Methods
=======

Our systematic review and meta-analysis was reported according to the recommendations of the PRISMA statement.[@b9-jpr-11-2463]

Outcome measures
----------------

The incidence of POST during the immediate 24-hour postoperative period was defined as primary endpoint, while the incidence of hoarseness, postoperative nausea and vomiting (PONV), cough, and adverse events were defined as secondary endpoints.

Data collection and analysis
----------------------------

Keywords were searched in Embase, PubMed, and Cochrane Library from their inception to December 12, 2017. RCTs were further identified by Cochrane Highly Sensitive Search Strategies.[@b10-jpr-11-2463] Keywords and MeSH terms were used in combination as follows: 1) corticosteroid, glucocorticoid, steroid, or dexamethasone; AND 2) sore throat, or sore throats, as shown in [Table S1](#SD4-jpr-11-2463){ref-type="supplementary-material"}. Additional studies were identified by searching Authors' names, "related articles" function, and screening the reference lists.

Section criteria
----------------

RCTs written in the English language assessing the prophylactic impact of dexamethasone vs placebo without other antiemetics, dexamethasone vs placebo plus concomitant administration of a different drug, dexamethasone vs a different drug, dexamethasone plus a different drug vs dexamethasone, or comparisons using different doses of dexamethasone for POST in patients with tracheal intubation of general anesthesia undergoing surgery except tonsillectomy were included. Exclusion criteria were as follows: 1) non-RCTs; 2) studies including patients undergoing tonsillectomy or laryngeal surgery; 3) studies without available data; 4) overlapping data; or 5) letters, reviews, case reports, and expert opinions.

Data extraction and management
------------------------------

The information and data we obtained were extracted from included studies by by Yaofei Jiang and Ruoxi Chen, and a third investigator was used to judge any disagreements. For each study, we recorded information and data of study population, interventions, and outcomes.

Assessment of quality of evidence in included studies
-----------------------------------------------------

Cochrane risk of bias instrument was used to assess the risk of bias for RCT quality by two reviewers independently.[@b11-jpr-11-2463] The following six items were examined including sequence generation, allocation concealment, double-blind evaluation, completeness of outcome data, selective reporting of outcome, and comparability of baseline characteristics between groups. The bias risk for each item was classified as high, low, or unclear. RCTs with no less than three items defined as high risk of bias were excluded for the meta-analysis. The seven matching criteria used to assess the baseline comparability between groups were as follows: age, gender, weight or BMI, American Society of Anaesthesiologists (ASA), intubation attempts, time of operation, and time of anesthesia. We defined baseline as incomparability if the number of nonmatching criteria was no less than 3.

Statistical analysis
--------------------

RevMan 5.0 and STATA 12.0 software were used to perform statistical analyses. Dichotomous variables were calculated with ORs and 95% CIs. We used random-effects model to pool data with statistical heterogeneity determined by the inconsistency index (*I*[@b2-jpr-11-2463]≥50%) and the Chi-squared test (*P*≤0.10). Subgroup analyses were conducted to determine the optimal dose and administration time. Sensitivity analyses were performed by omitting one study at a time. Begg's rank correlation test was used to assess the publication bias, determined as positive by Pr\>\|*z*\|≤0.1.[@b12-jpr-11-2463] The overall quality of evidence from available RCTs was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.[@b13-jpr-11-2463],[@b14-jpr-11-2463]

Results
=======

Trial identification
--------------------

A total of 645 articles were identified by comprehensive search. Fourteen RCTs were finally included for meta-analysis after screening of titles, abstracts, or full text articles ([Figure 1](#f1-jpr-11-2463){ref-type="fig"}).

Characteristics of included studies
-----------------------------------

The characteristics of the studies included are shown in [Table 1](#t1-jpr-11-2463){ref-type="table"}. Fourteen RCTs totaling 1,837 patients undergoing general anesthesia with tracheal intubation were included.

Patients classified as ASA class I or II were included in majority of the RCTs. Exclusion criteria were as follows: pregnancy, diabetes mellitus, obesity, and any contraindication to corticosteroid medications. Dexamethasone ranging from 4 to 0.2 mg/kg was administered intravenously in single or combination except one RCT[@b15-jpr-11-2463] administered locally. Timing of dexamethasone administration varied from 30 minutes before tracheal intubation to 30 minutes after tracheal intubation. Controls included placebo, ondansetron,[@b16-jpr-11-2463] magnesium sulfate,[@b17-jpr-11-2463] ketamine gargle,[@b18-jpr-11-2463] betamethasone gel,[@b19-jpr-11-2463] and ketorolac[@b20-jpr-11-2463] or a combination of these medications. Regarding the methodological quality of the RCTs, all showed low overall risks of bias ([Table 2](#t2-jpr-11-2463){ref-type="table"}).

Treatment effects
-----------------

### Primary endpoints

#### Incidence of POST: dexamethasone vs placebo, with or without concomitant drugs

The incidence of POST comparing dexamethasone vs placebo with or without concomitant drugs was reported in nine trials.[@b15-jpr-11-2463]--[@b25-jpr-11-2463] Compared with placebo, a statistical decrease in the incidence of POST at 24 hours was found in patients treated with dexamethasone, with or without concomitant drugs (OR 0.44, 95% CI 0.33--0.58, *P*\<0.00001; [Figure 2](#f2-jpr-11-2463){ref-type="fig"}). No statistical heterogeneity was found among studies (*P*=0.06, *I*[@b2-jpr-11-2463]=42%).

#### Incidence of POST: dexamethasone vs a different drug

The incidence of POST in patients receiving dexamethasone vs a different drug, including ondansetron,[@b16-jpr-11-2463] magnesium sulfate,[@b17-jpr-11-2463] ketamine gargle,[@b18-jpr-11-2463] betamethasone gel,[@b19-jpr-11-2463] or ketorolac,[@b20-jpr-11-2463] was described in five RCTs. Compared with these different drugs, no statistical difference in the incidence of POST at 24 hours was found in patients receiving dexamethasone (OR 0.70, 95% CI 0.46--1.07, *P*=0.10; [Figure 3](#f3-jpr-11-2463){ref-type="fig"}). No statistical heterogeneity was found among studies (*P*=0.49, *I*[@b2-jpr-11-2463]=0%).

#### Incidence of POST: dexamethasone plus a different drug vs dexamethasone

Data on incidence of POST comparing dexamethasone plus a different drug vs dexamethasone were reported in three trials.[@b16-jpr-11-2463],[@b18-jpr-11-2463],[@b26-jpr-11-2463] Compared with dexamethasone, a statistical decrease in the incidence of POST at 24 hours was found in patients treated with dexamethasone plus a different drug (OR 0.40, 95% CI 0.21--0.77, *P*=0.006; [Figure 4](#f4-jpr-11-2463){ref-type="fig"}). No statistical heterogeneity was found among studies (*P*=0.24, *I*[@b2-jpr-11-2463]=31%).

### Secondary endpoints

#### Incidence of hoarseness: dexamethasone vs placebo, with or without concomitant drugs

The incidence of hoarseness was reported in six RCTs.[@b15-jpr-11-2463],[@b17-jpr-11-2463],[@b18-jpr-11-2463],[@b20-jpr-11-2463],[@b24-jpr-11-2463],[@b25-jpr-11-2463],[@b27-jpr-11-2463] Compared with placebo, a significant reduction in the incidence of hoarseness was found in patients treated with dexamethasone with or without concomitant drugs (OR 0.42, 95% CI 0.31--0.58, *P*\<0.00001; [Figure 5](#f5-jpr-11-2463){ref-type="fig"}). No statistical heterogeneity was found among studies (*P*=0.16, *I*[@b2-jpr-11-2463]=32%).

#### Incidence of PONV: dexamethasone vs placebo, with or without concomitant drugs

The incidence of PONV was described in five RCTs.[@b16-jpr-11-2463],[@b20-jpr-11-2463]--[@b22-jpr-11-2463],[@b27-jpr-11-2463] Compared with placebo, a significant reduction in the incidence of PONV was found in patients treated with dexamethasone with or without concomitant drugs (OR 0.06, 95% CI 0.03--0.14, *P* \< 0.00001; [Figure 6](#f6-jpr-11-2463){ref-type="fig"}). No statistical heterogeneity was found among studies (*P*=0.19, *I*[@b2-jpr-11-2463]=35%).

#### Incidence of cough: dexamethasone vs placebo, with or without concomitant drugs

The incidence of cough was reported in three RCTs.[@b19-jpr-11-2463],[@b25-jpr-11-2463],[@b27-jpr-11-2463] Compared with placebo, comparable incidence of cough was found in patients treated with dexamethasone with or without concomitant drugs (OR 0.59, 95% CI 0.19--1.89, *P*=0.38; [Figure 7](#f7-jpr-11-2463){ref-type="fig"}). Statistical heterogeneity was found among studies (*P*=0.02, *I*[@b2-jpr-11-2463]=71%).

#### Incidence of adverse events: dexamethasone vs placebo with or without concomitant drugs

Data on postoperative blood glucose in patients receiving dexamethasone were described in one RCT.[@b17-jpr-11-2463] Compared with magnesium sulfate, statistically higher level of postoperative blood glucose was described in patients treated with dexamethasone. Compared with controls, comparable incidence of other adverse events such as dysphonia, dysphagia, itching, wound infection, diarrhea, headache, muscle pain, dizziness, drowsiness, urinary retention, and abdominal distension was found in patients treated with dexamethasone.

Subgroup analyses
-----------------

### Incidence of POST: dose of dexamethasone

Subgroup analyses according to the dose of dexamethasone ranging from 4 to 0.2 mg/kg indicated that dexamethasone ≥0.2 mg/kg and 0.1--0.2 mg/kg both significantly reduced the POST incidence compared with controls (0.1--0.2 mg/kg: OR 0.60, 95% CI 0.43--0.82; ≥0.2 mg/kg: OR 0.33, 95% CI 0.21--0.50), while dexamethasone ≤0.1 mg/kg did not (OR 0.57, 95% CI 0.31--1.03), as shown in [Figure 8](#f8-jpr-11-2463){ref-type="fig"}. Dexamethasone ≥0.2 mg/kg had a significantly greater effect on reducing the POST incidence than dexamethasone 0.1--0.2 mg/kg (0.1--0.2 mg/kg: OR 0.23, 95% CI 0.18--0.31; ≥0.2 mg/kg: OR 0.40, 95% CI 0.28--0.55; *P*\<0.00001), as shown in [Figure S1](#SD1-jpr-11-2463){ref-type="supplementary-material"}.

### Incidence of POST: timing of dexamethasone administration

Patients in most of the trials were administered with dexamethasone that varied from 30 minutes to immediately before induction of anesthesia. The incidence of POST in patients treated with dexamethasone administered 30 minutes prior to intubation vs 30 minutes after tracheal intubation was described in two RCTs.[@b28-jpr-11-2463],[@b29-jpr-11-2463] Comparable incidence of POST at 24 hours was found in patients receiving dexamethasone administered 30 minutes prior to intubation vs 30 minutes after tracheal intubation (OR 0.91, 95% CI 0.44--1.86, *P*=0.79; [Figure S2](#SD2-jpr-11-2463){ref-type="supplementary-material"}). No statistical heterogeneity was found among studies (*P*=0.66, *I*[@b2-jpr-11-2463]=0%).

Sensitivity analysis
--------------------

Sensitivity analyses omitting one study at a time demonstrated a significantly different result of meta-analysis on POST incidence comparing dexamethasone with a different drug.

Publication bias
----------------

No statistical publication bias was found among studies by Begg's rank correlation test, except for the data on POST incidence in patients treated with dexamethasone vs placebo, with or without concomitant drugs (Pr\>\|*z*\|=0.008) ([Table S2](#SD5-jpr-11-2463){ref-type="supplementary-material"}).

Quality of evidence
-------------------

As shown in [Table 3](#t3-jpr-11-2463){ref-type="table"}, quality of GRADE evidence from available RCTs, upgraded by large-effect or dose--response gradient, and downgraded by publication bias (Pr\>\|*z*\|≤0.1), indirectness (variations in study setting), imprecision (sensitivity analysis with a significantly different conclusion), or inconsistency (statistical heterogeneity among studies).

Reliability and conclusiveness of composite outcome result
----------------------------------------------------------

For conclusive and reliable meta-analysis, we calculated the optimal sample size by assuming a 40% control event rate of POST and a 25% relative risk reduction with 80% power and a two-sided *a*=0.01. Our calculations with sequential monitoring boundary crossing indicated that the cumulative evidence is reliable and conclusive ([Figure S3](#SD3-jpr-11-2463){ref-type="supplementary-material"}).

Discussion
==========

For patients experiencing tracheal intubation of general anesthesia, POST is a common but unpleasant complication. As glucocorticoid, dexamethasone has anti-inflammatory and analgesic impact. Therefore, prophylactic dexamethasone may be beneficial.

Our study demonstrated the safety and efficacy of prophylactic dexamethasone for patients undergoing sur gery requiring tracheal intubation of general anesthesia in reducing the incidence of POST, hoarseness, and PONV compared with placebo, with or without contaminant drugs. It may be explained that dexamethasone is anti-inflammatory and immunosuppressive agent, and it may exert its therapeutic actions through central inhibition of prostaglandin synthesis, by decreasing serotonin turnover in the central nervous system, and by influencing the systemic inflammatory response in favor of anti-inflammatory mediators.[@b5-jpr-11-2463],[@b6-jpr-11-2463],[@b30-jpr-11-2463]

Besides, our meta-analysis demonstrated comparable efficacy of dexamethasone in reducing POST as other drugs including ondansetron, magnesium sulfate, ketamine gargle, betamethasone gel, and ketorolac in this patient population. Among these latter, ondansetron exerts positive effects on pain relief as a Na channel blocker, a 5-HT3 receptor antagonist, and μ-opioid agonist,[@b31-jpr-11-2463] while magnesium sulfate[@b32-jpr-11-2463],[@b33-jpr-11-2463] and ketamine gargle[@b34-jpr-11-2463] both as *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor antagonists, betamethasone gel as corticosteroids, and ketorolac as an NSAID with analgesic and anti-inflammatory activities by inhibiting cyclooxygenase. Dexamethasone in combination with other drugs is most effective in reducing POST, perhaps due to its synergistic effects of pain relief through NMDA receptor antagonists.[@b34-jpr-11-2463],[@b35-jpr-11-2463] Although without other serious adverse events, dexamethasone was associated with increased level of postoperative blood glucose.

To determine the optimal dose of dexamethasone, subgroup analyses stratified by dose indicated more efficacies of higher doses of dexamethasone (≥0.2 mg/kg) compared with lower doses (0.1--0.2 mg/kg). In almost all trials included, dexamethasone was administered that varied from 30 minutes before tracheal intubation to 30 minutes after tracheal intubation. One of the concerns of dexamethasone administration is the potential for poor glycemic control. Postoperative glucose level measured at immediate postoperative period was higher in the dexamethasone group, as described by Park et al.[@b17-jpr-11-2463] Considering the results of the evaluated blood glucose, magnesium sulfate could be a valuable option in the prevention of POST when the use of dexamethasone may not be appropriate for its potential side effects.

Several limitations still exist in this meta-analysis. First, statistical heterogeneity on postoperative cough was found among studies, while publication bias was found on POST. Second, the RCTs in this meta-analysis mostly included healthy patients and excluded patients with pregnancy, diabetes mellitus, or contraindications for corticosteroids. Therefore, the prophylactic impact of dexamethasone on these patients is still unknown.

Conclusion
==========

Our meta-analysis demonstrated safety and efficacy of prophylactic dexamethasone in reducing the incidence of POST, hoarseness, and PONV in patients requiring tracheal intubation of general anesthesia compared with placebo, with or without concomitant drugs. Prophylactic dexamethasone ≥0.2 mg/kg administered intravenously within 30 minutes before or after induction of general anesthesia should be recommended as grade 1A evidence with safety and efficacy for patients without pregnancy, diabetes mellitus, or contraindications for corticosteroids.

Supplementary materials
=======================

###### 

Incidence of POST stratified according to dexamethasone dose: 0.1--0.2 mg/kg and ≥0.2 mg/kg.

**Abbreviations:** POST, postoperative sore throat; M-H, Mantel-Haenszel.

###### 

Incidence of POST with regard to timing of dexamethasone administration.

**Abbreviations:** POST, postoperative sore throat; M-H, Mantel-Haenszel.

###### 

Trial sequential analysis for POST.

**Abbreviation:** POST, postoperative sore throat.

###### 

Search strategy from its inception to December 2017

  ---- ------------------------------------------------------
  1    Randomized controlled trial \[pt\]
  2    Controlled clinical trial \[pt\]
  3    Randomized \[tiab\]
  4    Placebo \[tiab\]
  5    Drug therapy \[sh\]
  6    Randomly \[tiab\]
  7    Trial \[tiab\]
  8    Groups \[tiab\]
  9    \#1 or \#2 or \#3 or \#4 or \#5 or \#6 or \#7 or \#8
  10   Dexamethasone \[Mesh\]
  11   Dexamethasone \[tiab\]
  12   Corticosteroid \[tiab\]
  13   Glucocorticoid \[tiab\]
  14   Steroid \[tiab\]
  15   Steroids \[tiab\]
  16   \#10 or \#\#11 or \#12 or \#13 or \#14 or \#15
  17   Pharyngitis \[Mesh\]
  18   Sore throat \[tiab\]
  19   Sore throats \[tiab\]
  20   \#17 or \#18 or \#19
  21   \#9 and \#16 and \#20
  ---- ------------------------------------------------------

###### 

Begg's rank correlation test for publication bias

  Variable                                                            Pr\>\|*z*\|
  ------------------------------------------------------------------- ---------------------------------------------------
                                                                      
  Dexamethasone vs placebo (in addition to other drugs): POST         0.008[a](#tfn19-jpr-11-2463){ref-type="table-fn"}
  Dexamethasone vs placebo (in addition to other drugs): hoarseness   0.754
  Dexamethasone vs placebo (in addition to other drugs): PONV         0.734
  Dexamethasone vs placebo (in addition to other drugs): cough        0.734
  Dexamethasone vs a different drug: POST                             0.221
  Dexamethasone plus a different drug vs dexamethasone: POST          1.000

**Notes:**

Publication bias existed as Pr\>\|*z*\| value was ≤0.1.

**Abbreviations:** PONV, postoperative nausea and vomiting; POST, postoperative sore throat.

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow chart of literature search.](jpr-11-2463Fig1){#f1-jpr-11-2463}

![Incidence of POST at 24 hours grouped by concomitant drugs.\
**Abbreviations:** PONV, postoperative nausea and vomiting; POST, postoperative sore throat; M-H, Mantel-Haenszel.](jpr-11-2463Fig2){#f2-jpr-11-2463}

![Comparison of dexamethasone with other drugs.\
**Abbreviation:** M-H, Mantel-Haenszel.](jpr-11-2463Fig3){#f3-jpr-11-2463}

![Comparison of dexamethasone plus a different drug with dexamethasone.\
**Abbreviation:** M-H, Mantel-Haenszel.](jpr-11-2463Fig4){#f4-jpr-11-2463}

![Incidence of hoarseness.\
**Abbreviation:** M-H, Mantel-Haenszel.](jpr-11-2463Fig5){#f5-jpr-11-2463}

![Incidence of PONV.\
**Abbreviations:** PONV, postoperative nausea and vomiting; M-H, Mantel-Haenszel.](jpr-11-2463Fig6){#f6-jpr-11-2463}

![Incidence of cough.\
**Abbreviation:** M-H, Mantel-Haenszel.](jpr-11-2463Fig7){#f7-jpr-11-2463}

![POST according to dexamethasone dose.\
**Abbreviations:** POST, postoperative sore throat; M-H, Mantel-Haenszel.](jpr-11-2463Fig8){#f8-jpr-11-2463}

###### 

Characteristics of trials included in the meta-analysis

  Study                                        Sample size   Interventions                                                                                                            Studies divided
  -------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Yang et al (2017)[@b20-jpr-11-2463]          180           D 10 mg vs ketorolac 30 mg vs placebo for thyroidectomy of women, D IV at 5 minutes before induction                     Yang et al (2017) (1): D 10 mg vs placebo; Yang et al (2017) (2): D 10 mg vs ketorolac 30 mg preoperatively; Yang et al (2017) (3): D 10 mg vs ketorolac 30 mg postoperatively
  Thomas and Beevi (2007)[@b21-jpr-11-2463]    120           D 8 mg vs placebo for abdominal and lower limb surgeries, D IV                                                           Tomas and Beevi (2007): D 8 mg vs placebo
  Tabari et al (2013)[@b19-jpr-11-2463]        225           D vs betamethasone gel vs placebo for elective abdominal surgery, D IV                                                   Tabari et al (2013) (1): D vs placebo; Tabari et al (2013) (2): D vs betamethasone gel
  Singh et al (2008)[@b22-jpr-11-2463]         50            D 10 mg vs placebo for laparoscopic cholecystectomy, D IV at 1 minute before induction                                   Singh et al (2008): D 10 mg vs placebo
  Safavi et al (2014)[@b18-jpr-11-2463]        140           D 0.2 mg/kg vs gargled 40 mg ketamine vs gargled 40 mg ketamine plus D 0.2 mg/kg vs placebo for elective surgery, D IV   Safavi et al (2014) (1): D 0.2 mg/kg vs placebo; Safavi et al (2014) (2): D 0.2 mg/kg vs gargled 40 mg ketamine; Safavi et al (2014) (3): gargled 40 mg ketamine plus D 0.2 mg/kg vs gargled 40 mg ketamine; Safavi et al (2014) (4): gargled 40 mg ketamine plus D 0.2 mg/kg vs D 0.2 mg/kg
  Ruangsin et al (2012)[@b23-jpr-11-2463]      105           D 4 mg vs D 8 mg vs placebo for elective surgery, D IV preoperatively                                                    Ruangsin et al (2012) (1): D 4 mg vs placebo; Ruangsin et al (2012) (2): D 8 mg vs placebo
  Park et al (2015)[@b17-jpr-11-2463]          146           D 8 mg vs magnesium sulfate for lumbar spinal surgery, D IV at 10 minutes before induction                               Park et al (2015): D 8 mg vs magnesium sulfate
  Park et al (2010)[@b29-jpr-11-2463]          66            D 10 mg at 30 minutes before vs after intubation for elective laparoscopic cholecystectomy, D IV                         Park et al (2010): D 10 mg at 30 minutes before vs after intubation
  Park et al (2008)[@b24-jpr-11-2463]          166           D 0.2 mg/kg vs D 0.1 mg/kg vs placebo, D IV before induction for thoracic surgery                                        Park et al (2008) (1): D 0.1 mg/kg vs placebo; Park et al (2008) (2): D 0.2 mg/kg vs placebo
  de Oliveira et al (2011)[@b27-jpr-11-2463]   106           D 0.1 mg/kg vs D 0.05 mg/kg vs placebo, D IV before induction for ambulatory surgery                                     de Oliveira et al (2011) (1): D 0.05 mg/kg vs placebo; de Oliveira et al (2011) (2): D 0.1 mg/kg vs placebo
  Lee et al (2017)[@b26-jpr-11-2463]           226           D 10 mg and P 1,000 mg vs D 10 mg, D IV at 30 minutes before induction for urologic surgery                              Lee et al (2017): D 10 mg and P 1,000 mg vs D 10 mg
  Gautam et al (2008)[@b16-jpr-11-2463]        142           D 8 mg plus O 4 mg vs D 8 mg vs O 4 mg for elective laparoscopic cholecystectomy, D IV just before induction             Gautam et al (2008) (1): D 8 mg vs O 4 mg; Gautam et al (2008) (2): D 8 mg plus O 4 mg vs O 4 mg; Gautam et al (2008) (3): D 8 mg plus O 4 mg vs D 8 mg
  Eidi et al (2014)[@b28-jpr-11-2463]          70            D 8 mg before vs after intubation for tympanoplasty surgery, D IV                                                        Eidi et al (2014): D 8 mg before vs after intubation
  Bagchi et al (2012)[@b25-jpr-11-2463]        95            D 0.2 mg/kg vs placebo for elective surgeries, D IV just before induction                                                Bagchi et al (2012): D 0.2 mg/kg vs placebo

**Abbreviations:**D, dexamethasone; IV, intravenous; O, ondansetron; P, paracetamol.

###### 

Quality of evidence in included studies

  Included studies                             Country    Sequence generation   Allocation concealment   Double blinding   Complete outcome data   No selective reporting   Baseline comparability   Risk of bias
  -------------------------------------------- ---------- --------------------- ------------------------ ----------------- ----------------------- ------------------------ ------------------------ --------------
                                                                                                                                                                                                     
  Yang et al (2017)[@b20-jpr-11-2463]          Korea      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Thomas and Beevi (2007)[@b21-jpr-11-2463]    India      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Tabari et al (2013)[@b19-jpr-11-2463]        Iran       Adequate              Adequate                 Unclear           Yes                     Yes                      Unclear                  Low
  Singh et al (2008)[@b22-jpr-11-2463]         India      Adequate              Adequate                 Unclear           Yes                     Yes                      Yes                      Low
  Safavi et al (2014)[@b18-jpr-11-2463]        Iran       Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Ruangsin et al (2012)[@b23-jpr-11-2463]      Thailand   Adequate              Adequate                 Unclear           Yes                     Yes                      Yes                      Low
  Park et al (2015)[@b17-jpr-11-2463]          Korea      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Park et al (2010)[@b29-jpr-11-2463]          Korea      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Park et al (2008)[@b24-jpr-11-2463]          Korea      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  de Oliveira et al (2011)[@b27-jpr-11-2463]   USA        Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Lee et al (2017)[@b26-jpr-11-2463]           Korea      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Gautam et al (2008)[@b16-jpr-11-2463]        Nepal      Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Eidi et al (2014)[@b28-jpr-11-2463]          Iran       Adequate              Adequate                 Yes               Yes                     Yes                      Yes                      Low
  Bagchi et al (2012)[@b25-jpr-11-2463]        India      Adequate              Adequate                 Unclear           Yes                     Yes                      Yes                      Low

###### 

GRADE evidence

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients: undergoing surgery except tonsillectomy with tracheal intubation of general anesthesia\                                                                                                                                                                                                       
  Settings: evidence from Korea, India, Iran, Thailand, USA, and Nepal\                                                                                                                                                                                                                                   
  Intervention: dexamethasone\                                                                                                                                                                                                                                                                            
  Comparison: placebo                                                                                                                                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------- -------------- ------------------------------ ---------------------- ---------------------- ------------------------------------------------------------------------------------------------------- --
                                                                                                      Assumed risk   Corresponding risk                                                                                                                                                                   

                                                                                                      **Control**    **Dexamethasone**                                                                                                                                                                    

  Dexamethasone vs placebo (in addition to other antiemetics): POST                                   400 1,000      per 227 per 1,000 (181--279)   OR 0.44 (0.33--0.58)   1,090 (nine studies)   ⊕⊕⊕⊕ high[a](#tfn8-jpr-11-2463){ref-type="table-fn"}--[c](#tfn10-jpr-11-2463){ref-type="table-fn"}      

  Dexamethasone vs a different drug: POST                                                             223 1,000      per 167 per 1,000 (117--235)   OR 0.70 (0.46--1.07)   639 (five studies)     low ⊕⊕⊝⊝ low[d](#tfn11-jpr-11-2463){ref-type="table-fn"},[e](#tfn12-jpr-11-2463){ref-type="table-fn"}   

  Dexamethasone plus a different drug vs dexamethasone: POST                                          164 1,000      per 73 per 1,000 (40--131)     OR 0.40 (0.21--0.77)   390 (three studies)    ⊕⊕⊝⊝ high[f](#tfn13-jpr-11-2463){ref-type="table-fn"},[g](#tfn14-jpr-11-2463){ref-type="table-fn"}      

  Dexamethasone vs placebo, with or without concomitant drugs: hoarseness                             475 1,000      per 275 per 1,000 (219--344)   OR 0.42 (0.31--0.58)   833 (six studies)      ⊕⊕⊕⊕ high[h](#tfn15-jpr-11-2463){ref-type="table-fn"}                                                   

  Dexamethasone vs placebo, with or without concomitant drugs: PONV                                   400 1,000      per 38 per 1,000 (20--85)      OR 0.06 (0.03--0.14)   485 (five studies)     ⊕⊕⊕⊕ low[i](#tfn16-jpr-11-2463){ref-type="table-fn"}                                                    

  Dexamethasone vs placebo, with or without concomitant drugs: cough                                  469 1,000      per 343 per 1,000 (144--625)   OR 0.59 (0.19--1.89)   387 (three studies)    ⊕⊕⊝⊝[j](#tfn17-jpr-11-2463){ref-type="table-fn"}                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

**Notes:** Pr\>\|*z*\|=0.008.

OR 0.44, 95% CI 0.33--0.58, *P*\<0.00001.

Subgroup analyses stratified by dose of dexamethasone demonstrated that dexamethasone ≥0.2 mg/kg had a significantly greater effect.

Comparing dexamethasone with different drugs.

Sensitivity analysis omitting the trial of Tabari et al (2013) demonstrated a significantly different result with OR 0.64 (0.41--0.98).

Comparing different drugs plus dexamethasone with dexamethasone.

Sensitivity analysis omitting the trial of Safavi et al (2014) demonstrated a significant result with OR 0.54 (0.27--1.09).

OR 0.42, 95% CI 0.31--0.58, *P*\<0.00001.

OR 0.06, 95% CI 0.03--0.14, *P*\<0.00001.

Significant heterogeneity between studies (*P*=0.02, *I*[@b2-jpr-11-2463]=71%).

**Abbreviations:** PONV, postoperative nausea and vomiting; POST, postoperative sore throat; GRADE, Grading of Recommendations Assessment, Development and Evaluation.

[^1]: These authors contributed equally to this work
